Claims
- 1. An antiviral composition, comprising a long-chain aliphatic compound and a nucleotide analog in a pharmaceutically acceptable carrier.
- 2. The composition of claim 1, wherein the long-chain aliphatic compound is selected from the group consisting of C18-C28 primary alcohols, erucyl alcohol, brassidyl alcohol, n-docosane, n-docosanoic acid, erucamide, stearic acid, and mixtures thereof.
- 3. The composition of claim 1, wherein the aliphatic compound is present at a concentration of from about 0.05% to about 40%.
- 4. The composition of claim 1, wherein the nucleotide analog is present at a concentration in a range of about 0.1% to about 10%.
- 5. The composition of claim 1, wherein the nucleotide analog is selected from the group consisting of adefovir and cidofovir.
- 6. The composition of claim 1, further comprising a nucleoside analog.
- 7. The composition of claim 6, wherein the nucleoside analog is selected from the group consisting of acyclovir, azidothymidine, brivudin, ddC, ddI, famciclovir, ganciclovir, idoxuridine, lamivudine, lobucavir, penciclovir, ribavirin, sorivudine, trifluridine, valaciclovir, and Ara A.
- 8. The composition of claim 1, further comprising a nonionic surfactant.
- 9. The composition of claim 8, wherein the nonionic surfactant comprises a difunctional block-polymer that is a polyoxyalkylene derivative of propylene glycol having a molecular weight of about 1,000 to about 25,000.
- 10. The composition of claim 8, wherein the nonionic surfactant comprises a block copolymer of ethylene oxide and propylene oxide having a molecular weight of between 6,000 and 12,000.
- 11. The composition of claim 8, wherein the nonionic surfactant is selected from the group consisting of octoxynol-9 and octoxynol-10.
- 12. The composition of claim 1, further comprising a penetration enhancer.
- 13. The composition of claim 1, further comprising other agents selected from the group consisting of anti-microbial agents, other antiviral agents, anti-fungal agents, antioxidants, buffering agents, sunscreens, cosmetic agents, fragrances, lubricants, moisturizers, drying agents, and thickening agents.
- 14. The composition of claim 1, wherein the long-chain aliphatic compound comprises n-docosanol.
- 15. A method of treating a viral infection, the method comprising the step of administering a medicament to a human in need thereof, the medicament comprising an antiviral composition comprising a long-chain aliphatic compound and a nucleotide analog in a pharmaceutically acceptable carrier.
- 16. The method of claim 15, wherein the long-chain aliphatic compound and the nucleotide analog are independently adapted for administration from one to five times per day via a route selected from the group consisting of topical, oral, mucosal, transmembranal penetration and intravenous.
- 17. The method of claim 15, wherein the medicament is administered at a dose of about 0.01 to about 10 grams with a frequency of about one to about five times per day for a period of about one to about fourteen days.
- 18. The method of claim 15, wherein the medicament is administered via a route selected from the group consisting of topical, oral, mucosal, transmembranal penetration and intravenous.
- 19. An antiviral composition, comprising a C21-C28 primary alcohol and a nucleotide analog or a nucleoside analog in a pharmaceutically acceptable carrier.
- 20. The composition of claim 19, wherein the C21-C28 primary alcohol comprises n-docosanol.
- 21. The composition of claim 19, wherein the aliphatic compound is present at a concentration of from about 0.05% to about 40%.
- 22. The composition of claim 19, wherein the nucleoside analog or nucleotide analog is selected from the group consisting of acyclovir, adefovir, azidothymidine, brivudin, cidofovir, ddC, ddI, famciclovir, ganciclovir, idoxuridine, lamivudine, lobucavir, penciclovir, ribavirin, sorivudine, trifluridine, valaciclovir, and Ara A.
Parent Case Info
[0001] This is a continuation-in-part of pending patent application Ser. No. 08/916,624, filed on Aug. 22, 1997, which claims priority under 119(e) to Provisional Application No. 60/064,850 with a priority date of Sept. 17, 1996.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60064850 |
Sep 1996 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09265992 |
Mar 1999 |
US |
Child |
10197283 |
Jul 2002 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
08916624 |
Aug 1997 |
US |
Child |
09265992 |
Mar 1999 |
US |